



Alzinova presents ALZ-201 antibody's unique binding profile at major international Alzheimer's conference

Alzinova AB (publ) ("Alzinova" or the "Company") presents data for the Company's preclinical antibody candidate ALZ-201 at the annual Alzheimer's conference CTAD, Clinical Trials in Alzheimer's Disease, to be held in San Francisco from 29 November to 2 December. Alzinova's Chief Scientific Officer Anders Sandberg will summarise the antibody's unique binding profile in a poster presentation titled "ALZ-201, a monoclonal antibody therapy for specific neutralization of toxic amyloid- β in Alzheimer's disease".

Alzinova's strategy, to develop an effective and safe treatment for Alzheimer's disease, focuses specifically on the toxic forms of amyloid-beta, the oligomers, which have attracted increasing interest. Preclinical data show that the Company's drug candidates in development have "best-in-class" potential, and clinical results from other players in the field reinforce the Company's strategy. The Company has participated in several partnering and investor meetings this fall and will now present a poster at CTAD.

The poster summarises the development of the monoclonal antibody ALZ-201 and its unique binding profile in relation to other drug candidates in development. The data show that ALZ-201 differs significantly from lecanemab, aducanumab, and gantenerumab in that, unlike these, binds specifically to a small portion of the amyloid beta known as oligomers. With this targeted binding profile, ALZ-201 has a strong neutralising effect on the toxic form of amyloid beta extracted from the brains of deceased Alzheimer's patients. Specificity for the amyloid beta that is toxic, is thought to be necessary to obtain a good therapeutic effect in patients with Alzheimer's disease.

CTAD is a highly regarded annual Alzheimer's conference that will be held this year from 29 November to 2 December 2022 in San Francisco. The conference, which is focused on clinical development of new drug candidates for the treatment of Alzheimer's disease, attracts many prominent leaders in research, industry, and academia.

For more information, please contact:

Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail: kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.



About Alzinova

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A β CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Corpura. For more information about Alzinova, please visit: www.alzinova.com

Attachments

Alzinova presents ALZ-201 antibody's unique binding profile at major international Alzheimer's conference